# US 11,173,182 B1 · Placenta-derived adherent cell exosomes and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,173,182 B1
- Document ID: US11173182B1
- Status: Granted
- Kind: B1
- Application number: 16/740,054
- Filed: 2020-01-10
- Granted: 2021-11-16
- Earliest claimed: 2014-10-09
- Assignees: Celularity Inc.
- Applicants: Celularity Inc.
- Inventors: Eric Law; Andrew Morschauser; Aleksander Francki; Jennifer Paredes; Kathy Karasiewicz-Mendez; Allan Reduta; Vladimir Jankovic; Ivana Djuretic; Robert J. Hariri
- Web page: https://patentgrep.com/patent/US11173182B1

## CPC

- A61K 35/50: Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- C12N 5/0605: {Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly}
- C12N 5/0645: {Macrophages, e.g. Kuepfer cells in the liver; Monocytes}
- C12N 5/0668: {Mesenchymal stem cells from other natural sources}
- C12N 5/069: {Vascular Endothelial cells}
- C12N 2502/025: extra-embryonic cells, e.g. amniotic epithelium, placental cells, Wharton's jelly
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided herein are compositions of placenta-derived adherent cell exosomes and methods of making and using the same. In one aspect, provided herein are compositions comprising exosomes produced by and/or derived from placental cells, e.g., placenta-derived adherent cells. In certain embodiments, the exosomes provided herein are produced by placenta-derived adherent cells that have been cultured in vitro for, e.g., 1, 2, 3, 4, 5, 6 or more passages.

## Claims

### Claim 1

A composition comprising exosomes derived from CD10+, CD200+, CD105+, CD34− human placenta derived adherent cells, wherein said exosomes are CD9+, CD10+, CD13+, CD29+, CD44+, CD49b+, CD49c+, CD55+, CD59+, CD63+, CD73+, CD81+, CD82+, CD90+, CD98+, CD105+, CD141+, CD142+, CD151+, CD164+, CD295+, or CD200+.

### Claim 2 (depends on 1)

The composition of claim 1, wherein said exosomes are CD9+, CD10+, CD13+, CD29+, CD44+, CD49b+, CD49c+, CD55+, CD59+, CD63+, CD73+, CD81+, CD82+, CD90+, CD98+, CD105+, CD141+, CD142+, CD151+, CD164+, CD295+, and CD200+.

### Claim 3 (depends on 1)

The composition of claim 1, wherein said exosomes are additionally CD3−, CD1lb−, CD14−, CD19−, CD33−, CD192−, HLA-A−, HLA-B−, HLA-C−, HLA-DR−, CD11c− or CD34−.

### Claim 4 (depends on 1)

The composition of any of claim 1, wherein said exosomes are additionally CD3−, CD11b−, CD14−, CD19−, CD33−, CD192−, HLA-A−, HLA-B−, HLA-C−, HLA-DR−, CD11c and CD34−.

### Claim 5 (depends on 1)

The composition of claim 1, wherein said exosomes comprise non-coding RNA molecules.

### Claim 6 (depends on 5)

The composition of claim 5, wherein said RNA molecules are microRNAs.

### Claim 7 (depends on 6)

The composition of claim 6, wherein said microRNAs are miR-218-Sp, miR-133b, miR-422a, miR-564, miR-16-Sp, let-7a, miR-92, miR-142-3p, miR-451, miR-124-Sp, miR-223-3p, miR-630, miR-296-Sp, let-7b-3p or let-7d-3p.

### Claim 8 (depends on 1)

The composition of any of claim 1, wherein said exosomes comprise at least one marker molecule at a level at least two-fold higher than exosomes derived from mesenchymal stem cells.

### Claim 9 (depends on 1)

The composition of claim 1, wherein said placenta-derived adherent cells have been passaged more than 3 times.

### Claim 10 (depends on 1)

The composition of any of claim 1, wherein said placenta derived adherent cells have been maintained in culture for greater than 24 hours.

### Claim 11 (depends on 1)

The composition of claim 1, wherein at least 90% of said placenta-derived adherent cells are non-maternal in origin.

### Claim 12 (depends on 1)

The composition of claim 1, wherein at least 99% of said placenta-derived adherent cells are non-maternal in origin.

### Claim 13 (depends on 1)

The composition of any of claim 1 that is in a form suitable for intravenous administration.

### Claim 14

A composition comprising exosomes derived from CD10+, CD200+, CD105+, CD34− human placenta-derived adherent cells, wherein said exosomes are CD10+ and CD55+.